John D Boyce

List of Publications by Year
in descending order

109 papers	6,912 citations	66343 42 h-index	62596 80 g-index
110 all docs	110 docs citations	110 times ranked	6192 citing authors

#	Article	IF	Citations
1	Colistin Resistance in <i>Acinetobacter baumannii</i> Is Mediated by Complete Loss of Lipopolysaccharide Production. Antimicrobial Agents and Chemotherapy, 2010, 54, 4971-4977.	3.2	699
2	NetB, a New Toxin That Is Associated with Avian Necrotic Enteritis Caused by Clostridium perfringens. PLoS Pathogens, 2008, 4, e26.	4.7	494
3	Genetic Organization of Pasteurella multocida cap Loci and Development of a Multiplex Capsular PCR Typing System. Journal of Clinical Microbiology, 2001, 39, 924-929.	3.9	378
4	Pasteurella multocida pathogenesis: 125 years after Pasteur. FEMS Microbiology Letters, 2006, 265, 1-10.	1.8	319
5	Biological Cost of Different Mechanisms of Colistin Resistance and Their Impact on Virulence in Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2014, 58, 518-526.	3.2	218
6	Insertion Sequence IS <i>Aba11</i> Is Involved in Colistin Resistance and Loss of Lipopolysaccharide in Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2011, 55, 3022-3024.	3.2	191
7	Colistin-Resistant, Lipopolysaccharide-Deficient Acinetobacter baumannii Responds to Lipopolysaccharide Loss through Increased Expression of Genes Involved in the Synthesis and Transport of Lipoproteins, Phospholipids, and Poly-Î²-1,6- <i>N</i> -Acetylglucosamine. Antimicrobial Agents and Chemotherapy, 2012, 56, 59-69.	3.2	173
8	Pasteurella multocida: Diseases and Pathogenesis. Current Topics in Microbiology and Immunology, 2012, 361, 1-22.	1.1	167
9	The Burkholderia pseudomallei Type III Secretion System and BopA Are Required for Evasion of LC3-Associated Phagocytosis. PLoS ONE, 2011, 6, e17852.	2.5	140
10	Stimulation of autophagy suppresses the intracellular survival of<i>Burkholderia pseudomallei</i>in mammalian cell lines. Autophagy, 2008, 4, 744-753.	9.1	134
11	Analysis of the DNA sequence, gene expression, origin of replication and modular structure of the Lactococcus lactis lytic bacteriophage sk1. Molecular Microbiology, 1997, 26, 49-64.	2.5	133
12	The molecular and cellular basis of pathogenesis in melioidosis: how does<i>Burkholderia pseudomallei</i>cause disease?. FEMS Microbiology Reviews, 2009, 33, 1079-1099.	8.6	131
13	The Capsule Is a Virulence Determinant in the Pathogenesis of Pasteurella multocida M1404 (B:2). Infection and Immunity, 2000, 68, 3463-3468.	2.2	126
14	Role of Capsule in the Pathogenesis of Fowl Cholera Caused by Pasteurella multocida Serogroup A. Infection and Immunity, 2001, 69, 2487-2492.	2.2	125
15	Mechanisms of Polymyxin Resistance. Advances in Experimental Medicine and Biology, 2019, 1145, 55-71.	1.6	118
16	Outer membrane proteins of Pasteurella multocida. Veterinary Microbiology, 2010, 144, 1-17.	1.9	112
17	Strategies for Intracellular Survival of Burkholderia pseudomallei. Frontiers in Microbiology, 2011, 2, 170.	3.5	106
18	Different surface charge of colistin-susceptible and -resistant Acinetobacter baumannii cells measured with zeta potential as a function of growth phase and colistin treatment. Journal of Antimicrobial Chemotherapy, 2011, 66, 126-133.	3.0	99

#	Article	IF	Citations
19	Development of a Rapid Multiplex PCR Assay To Genotype Pasteurella multocida Strains by Use of the Lipopolysaccharide Outer Core Biosynthesis Locus. Journal of Clinical Microbiology, 2015, 53, 477-485.	3.9	89
20	Genomic Scale Analysis of Pasteurella multocida Gene Expression during Growth within the Natural Chicken Host. Infection and Immunity, 2002, 70, 6871-6879.	2.2	88
21	Identification of Novel Acinetobacter baumannii Type VI Secretion System Antibacterial Effector and Immunity Pairs. Infection and Immunity, 2018, 86, .	2.2	88
22	The transcriptomic response of <i>Acinetobacter baumannii</i> to colistin and doripenem alone and in combination in an <i>in vitro</i> pharmacokinetics/pharmacodynamics model. Journal of Antimicrobial Chemotherapy, 2015, 70, 1303-1313.	3.0	85
23	Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens. Scientific Reports, 2016, 6, 26233.	3.3	82
24	Analysis of thePasteurella multocida outer membrane sub-proteome and its response to thein vivo environment of the natural host. Proteomics, 2006, 6, 870-880.	2.2	75
25	Necrotic Enteritis-Derived Clostridium perfringens Strain with Three Closely Related Independently Conjugative Toxin and Antibiotic Resistance Plasmids. MBio, 2011, 2, .	4.1	75
26	Synergistic killing of NDM-producing MDR<i>Klebsiella pneumoniae</i>by two â€˜oldâ€™ antibioticsâ€"polymyxin B and chloramphenicol. Journal of Antimicrobial Chemotherapy, 2015, 70, 2589-2597.	3.0	73
27	Fis Is Essential for Capsule Production in Pasteurella multocida and Regulates Expression of Other Important Virulence Factors. PLoS Pathogens, 2010, 6, e1000750.	4.7	71
28	Pasteurella multocida capsule: composition, function and genetics. Journal of Biotechnology, 2000, 83, 153-160.	3.8	69
29	Lipopolysaccharide-Deficient Acinetobacter baumannii Shows Altered Signaling through Host Toll-Like Receptors and Increased Susceptibility to the Host Antimicrobial Peptide LL-37. Infection and Immunity, 2013, 81, 684-689.	2.2	68
30	Genome sequence and identification of candidate vaccine antigens from the animal pathogen Dichelobacter nodosus. Nature Biotechnology, 2007, 25, 569-575.	17.5	66
31	A Heptosyltransferase Mutant of Pasteurella multocida Produces a Truncated Lipopolysaccharide Structure and Is Attenuated in Virulence. Infection and Immunity, 2004, 72, 3436-3443.	2.2	62
32	Comparative transcriptomic analysis of Porphyromonas gingivalisbiofilm and planktonic cells. BMC Microbiology, 2009, 9, 18.	3.3	61
33	Sequence analysis of the Lactococcus lactis temperate bacteriophage BK5-T and demonstration that the phage DNA has cohesive ends. Applied and Environmental Microbiology, 1995, 61, 4089-4098.	3.1	61
34	Identification of prophage genes expressed in lysogens of the Lactococcus lactis bacteriophage BK5-T. Applied and Environmental Microbiology, 1995, 61, 4099-4104.	3.1	55
35	Pasteurella multocida lipopolysaccharide: The long and the short of it. Veterinary Microbiology, 2011, 153, 109-115.	1.9	54
36	Signature-Tagged Mutagenesis of Pasteurella multocida Identifies Mutants Displaying Differential Virulence Characteristics in Mice and Chickens. Infection and Immunity, 2003, 71, 5440-5446.	2.2	52

#	Article	IF	Citations
37	Novel Approach To Optimize Synergistic Carbapenem-Aminoglycoside Combinations against Carbapenem-Resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2015, 59, 2286-2298.	3.2	52
38	Global metabolic analyses identify key differences in metabolite levels between polymyxin-susceptible and polymyxin-resistant Acinetobacter baumannii. Scientific Reports, 2016, 6, 22287.	3.3	49
39	The Myriad Properties of Pasteurella multocida Lipopolysaccharide. Toxins, 2017, 9, 254.	3.4	48
40	Pasteurella multocida Expresses Two Lipopolysaccharide Glycoforms Simultaneously, but Only a Single Form Is Required for Virulence: Identification of Two Acceptor-Specific Heptosyl I Transferases. Infection and Immunity, 2007, 75, 3885-3893.	2.2	47
41	Genetic organisation of the capsule biosynthetic locus of Pasteurella multocida M1404 (B:2). Veterinary Microbiology, 2000, 72, 121-134.	1.9	45
42	Comparative Genomic Analysis of Asian Haemorrhagic Septicaemia-Associated Strains of Pasteurella multocida Identifies More than 90 Haemorrhagic Septicaemia-Specific Genes. PLoS ONE, 2015, 10, e0130296.	2.5	45
43	Decoration of<i>Pasteurella multocida</i>Lipopolysaccharide with Phosphocholine Is Important for Virulence. Journal of Bacteriology, 2007, 189, 7384-7391.	2.2	44
44	The Key Surface Components of Pasteurella multocida: Capsule and Lipopolysaccharide. Current Topics in Microbiology and Immunology, 2012, 361, 39-51.	1.1	42
45	The RNA-Binding Chaperone Hfq Is an Important Global Regulator of Gene Expression in Pasteurella multocida and Plays a Crucial Role in Production of a Number of Virulence Factors, Including Hyaluronic Acid Capsule. Infection and Immunity, 2016, 84, 1361-1370.	2.2	40
46	Spontaneous deletion mutants of the Lactococcus lactis temperate bacteriophage BK5-T and localization of the BK5-T attP site. Applied and Environmental Microbiology, 1995, 61, 4105-4109.	3.1	39
47	Natural Transformation of Gallibacterium anatis. Applied and Environmental Microbiology, 2012, 78, 4914-4922.	3.1	38
48	Pathogenomics of Pasteurella multocida. Current Topics in Microbiology and Immunology, 2012, 361, 23-38.	1.1	38
49	Global Gene Expression Profile of Acinetobacter baumannii During Bacteremia. Journal of Infectious Diseases, 2017, 215, S52-S57.	4.0	38
50	How does Pasteurella multocida respond to the host environment?. Current Opinion in Microbiology, 2006, 9, 117-122.	5.1	37
51	Identification of novel immunogens in Pasteurella multocida. Microbial Cell Factories, 2007, 6, 3.	4.0	37
52	Pasteurella multocida Heddleston Serovar 3 and 4 Strains Share a Common Lipopolysaccharide Biosynthesis Locus but Display both Inter- and Intrastrain Lipopolysaccharide Heterogeneity. Journal of Bacteriology, 2013, 195, 4854-4864.	2.2	37
53	In Vivo-Expressed Genes of Pasteurella multocida. Infection and Immunity, 2001, 69, 3004-3012.	2.2	36
54	Genomic-scale Analysis of Bacterial Gene and Protein Expression in the Host. Emerging Infectious Diseases, 2004, 10, 1357-1362.	4.3	36

#	Article	IF	Citations
55	Genomic Evidence for a Globally Distributed, Bimodal Population in the Ovine Footrot Pathogen Dichelobacter nodosus. MBio, 2014, 5, e01821-14.	4.1	36
56	Emergence of High-Level Colistin Resistance in an Acinetobacter baumannii Clinical Isolate Mediated by Inactivation of the Global Regulator H-NS. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	36
57	The Fimbrial Protein FlfA from Gallibacterium anatis Is a Virulence Factor and Vaccine Candidate. Infection and Immunity, 2013, 81, 1964-1973.	2.2	35
58	Structural and Genetic Basis for the Serological Differentiation of <i>Pasteurella multocida</i> Heddleston Serotypes 2 and 5. Journal of Bacteriology, 2009, 191, 6950-6959.	2.2	34
59	Genomic-scale analysis of Pasteurella multocida gene expression during growth within liver tissue of chickens with fowl cholera. Microbes and Infection, 2004, 6, 290-298.	1.9	32
60	Systematic Identification and Analysis of Acinetobacter baumannii Type VI Secretion System Effector and Immunity Components. Frontiers in Microbiology, 2019, 10, 2440.	3.5	32
61	Screening of 71 P. multocida Proteins for Protective Efficacy in a Fowl Cholera Infection Model and Characterization of the Protective Antigen PlpE. PLoS ONE, 2012, 7, e39973.	2.5	32
62	Sequence Analysis and Molecular Characterization of the Lactococcus lactis Temperate Bacteriophage BK5-T. Applied and Environmental Microbiology, 2001, 67, 3564-3576.	3.1	31
63	Functional characterization of HgbB, a new hemoglobin binding protein of Pasteurella multocida. Microbial Pathogenesis, 2003, 34, 287-296.	2.9	31
64	Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	31
65	Polymyxins Bind to the Cell Surface of Unculturable <i>Acinetobacter baumannii</i> and Cause Unique Dependent Resistance. Advanced Science, 2020, 7, 2000704.	11.2	31
66	Effect of colistin exposure and growth phase on the surface properties of live Acinetobacter baumannii cells examined by atomic force microscopy. International Journal of Antimicrobial Agents, 2011, 38, 493-501.	2.5	30
67	Pasteurella multocida Heddleston serovars 1 and 14 express different lipopolysaccharide structures but share the same lipopolysaccharide biosynthesis outer core locus. Veterinary Microbiology, 2011, 150, 289-296.	1.9	30
68	Identification of a DNA-Damage-Inducible Regulon in Acinetobacter baumannii. Journal of Bacteriology, 2013, 195, 5577-5582.	2.2	30
69	Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	30
70	Role for the Burkholderia pseudomallei Type Three Secretion System Cluster 1 bpscN Gene in Virulence. Infection and Immunity, 2011, 79, 3659-3664.	2.2	28
71	Identification of Novel Glycosyltransferases Required for Assembly of the <i>Pasteurella multocida</i> A:1 Lipopolysaccharide and Their Involvement in Virulence. Infection and Immunity, 2009, 77, 1532-1542.	2.2	27
72	Beclin 1 Is Required for Starvation-Enhanced, but Not Rapamycin-Enhanced, LC3-Associated Phagocytosis of Burkholderia pseudomallei in RAW 264.7 Cells. Infection and Immunity, 2013, 81, 271-277.	2.2	26

#	Article	IF	Citations
73	Determination of the small RNA GcvB regulon in the Gram-negative bacterial pathogen <i>Pasteurella multocida</i> and identification of the GcvB seed binding region. Rna, 2018, 24, 704-720.	3.5	26
74	Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	26
75	Protective efficacy afforded by live Pasteurella multocida vaccines in chickens is independent of lipopolysaccharide outer core structure. Vaccine, 2016, 34, 1696-1703.	3.8	25
76	Comparable Efficacy and Better Safety of Double Î²-Lactam Combination Therapy versus Î²â€‘Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	24
77	Acapsular Pasteurella multocida B:2 Can Stimulate Protective Immunity against Pasteurellosis. Infection and Immunity, 2001, 69, 1943-1946.	2.2	20
78	FimR and FimS: Biofilm Formation and Gene Expression in<i>Porphyromonas gingivalis</i>. Journal of Bacteriology, 2010, 192, 1332-1343.	2.2	20
79	Perturbation of the two-component signal transduction system, BprRS, results in attenuated virulence and motility defects in Burkholderia pseudomallei. BMC Genomics, 2016, 17, 331.	2.8	19
80	Characterization of two lipoproteins in Pasteurella multocida. Microbes and Infection, 2004, 6, 58-67.	1.9	17
81	Vaccination against fowl cholera with acapsular Pasteurella multocida A:1. Vaccine, 2005, 23, 2751-2755.	3.8	17
82	Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five Î²-Lactams Simultaneously in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> and <i>Enterobacter cloacae</i>. MBio, 2020, 11, .	4.1	17
83	Evolutionary Analysis of Burkholderia pseudomallei Identifies Putative Novel Virulence Genes, Including a Microbial Regulator of Host Cell Autophagy. Journal of Bacteriology, 2013, 195, 5487-5498.	2.2	16
84	Burkholderia pseudomallei Type III Secretion System Cluster 3 ATPase BsaS, a Chemotherapeutic Target for Small-Molecule ATPase Inhibitors. Infection and Immunity, 2015, 83, 1276-1285.	2.2	16
85	Whatâ€™s the risk? Identifying potential human pathogens within grey-headed flying foxes faeces. PLoS ONE, 2018, 13, e0191301.	2.5	16
86	Characterization of Two Novel Lipopolysaccharide Phosphoethanolamine Transferases in Pasteurella multocida and Their Role in Resistance to Cathelicidin-2. Infection and Immunity, 2017, 85, .	2.2	14
87	Synergy of the Polymyxin-Chloramphenicol Combination against New Delhi Metallo-Î²-Lactamase-Producing <i>Klebsiella pneumoniae</i> Is Predominately Driven by Chloramphenicol. ACS Infectious Diseases, 2021, 7, 1584-1595.	3.8	14
88	Characterization of the lipopolysaccharide from Pasteurella multocida Heddleston serovar 9: Identification of a proposed bi-functional dTDP-3-acetamido-3,6-dideoxy-Â-D-glucose biosynthesis enzyme. Glycobiology, 2012, 22, 332-344.	2.5	13
89	Structure and biosynthetic locus of the lipopolysaccharide outer core produced by Pasteurella multocida serovars 8 and 13 and the identification of a novel phospho-glycero moiety. Glycobiology, 2013, 23, 286-294.	2.5	13
90	Structural analysis of lipopolysaccharide produced by Heddleston serovars 10, 11, 12 and 15 and the identification of a new Pasteurella multocida lipopolysaccharide outer core biosynthesis locus, L6. Glycobiology, 2014, 24, 649-659.	2.5	12

#	Article	IF	Citations
91	Characterization of TolC Efflux Pump Proteins from <i>Pasteurella multocida</i>. Antimicrobial Agents and Chemotherapy, 2008, 52, 4166-4171.	3.2	11
92	In silico prediction of Gallibacterium anatis pan-immunogens. Veterinary Research, 2014, 45, 80.	3.0	11
93	The Pasteurella multocida nrfE Gene Is Upregulated during Infection and Is Essential for Nitrite Reduction but Not for Virulence. Journal of Bacteriology, 2005, 187, 2278-2285.	2.2	10
94	Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	10
95	Transcriptomic responses of a New Delhi metallo-Î²-lactamase-producing Klebsiella pneumoniae isolate to the combination of polymyxin B and chloramphenicol. International Journal of Antimicrobial Agents, 2020, 56, 106061.	2.5	10
96	Combating Multidrugâ€Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling. Clinical Pharmacology and Therapeutics, 2021, 109, 1000-1020.	4.7	10
97	Natural Selection in the Chicken Host Identifies 3-Deoxy- <scp>d</scp> - <i>manno</i> - Octulosonic Acid Kinase Residues Essential for Phosphorylation of <i>Pasteurella multocida</i> Lipopolysaccharide. Infection and Immunity, 2010, 78, 3669-3677.	2.2	9
98	Cell surface hydrophobicity of colistin-susceptible vs resistant Acinetobacter baumannii determined by contact angles: methodological considerations and implications. Journal of Applied Microbiology, 2012, 113, 940-951.	3.1	9
99	RNA-seq analysis of virR and revR mutants of Clostridium perfringens. BMC Genomics, 2016, 17, 391.	2.8	9
100	Characterization of the lipopolysaccharide produced by Pasteurella multocida serovars 6, 7 and 16: Identification of lipopolysaccharide genotypes L4 and L8. Glycobiology, 2015, 25, 294-302.	2.5	8
101	Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model. Journal of Global Antimicrobial Resistance, 2021, 26, 55-63.	2.2	7
102	Pan-transcriptomic analysis identified common differentially expressed genes of<i>Acinetobacter baumannii</i>in response to polymyxin treatments. Molecular Omics, 2020, 16, 327-338.	2.8	7
103	Genetic Organization of <i>Pasteurella multocida cap</i> Loci and Development of a Multiplex Capsular PCR Typing System. Journal of Clinical Microbiology, 2001, 39, 2377-2377.	3.9	6
104	The Burkholderia pseudomallei Proteins BapA and BapC Are Secreted TTSS3 Effectors and BapB Levels Modulate Expression of BopE. PLoS ONE, 2015, 10, e0143916.	2.5	5
105	The capsular polysaccharides of Pasteurella multocida serotypes B and E: Structural, genetic and serological comparisons. Glycobiology, 2021, 31, 307-314.	2.5	5
106	The Role and Targets of the RNA-Binding Protein ProQ in the Gram-Negative Bacterial Pathogen Pasteurella multocida. Journal of Bacteriology, 2022, 204, e0059221.	2.2	4
107	Genome-Wide Investigation of Pasteurella multocida Identifies the Stringent Response as a Negative Regulator of Hyaluronic Acid Capsule Production. Microbiology Spectrum, 2022, 10, e0019522.	3.0	4
108	Phosphorylation of Extracellular Proteins in Acinetobacter baumannii in Sessile Mode of Growth. Frontiers in Microbiology, 2021, 12, 738780.	3.5	3

#	Article	IF	Citations
109	Disruption of the Burkholderia pseudomallei two-component signal transduction system BbeR-BbeS leads to increased extracellular DNA secretion and altered biofilm formation. Veterinary Microbiology, 2020, 242, 108603.	1.9	2